Tvardi Therapeutics
TVRD
75 hedge funds and large institutions have $146M invested in Tvardi Therapeutics in 2015 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 32 increasing their positions, 12 reducing their positions, and 7 closing their positions.
46,400% more call options, than puts
Call options by funds: $465K | Put options by funds: $1K
214% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 7
167% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 12
31% more capital invested
Capital invested by funds: $112M → $146M (+$34.3M)
25% more funds holding
Funds holding: 60 → 75 (+15)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.33M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$3.92M |
| 3 |
CPM
Chesapeake Partners Management
Baltimore,
Maryland
|
+$3.51M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.14M |
| 5 |
WSA
Wall Street Associates
Lajolla,
California
|
+$2.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DPA
Devon Park Associates
|
-$5.99M |
| 2 |
DM
Deerfield Management
New York
|
-$4.76M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$3.13M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.55M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$874K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DM
76
Deerfield Management
New York
| – | -$4.76M | -13,155 | Closed |
|
|
77
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$2.55M | -7,045 | Closed |
|
|
HLA
78
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
| – | -$600K | -1,659 | Closed |
|
|
SM
79
Senvest Management
New York
| – | -$292K | -808 | Closed |
|
80
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$111K | -306 | Closed |
|
81
AllianceBernstein
Nashville,
Tennessee
| – | -$6K | -17 | Closed |
|
TVRD Hedge Fund Activity: Q2 2015 in Review
75 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2015, worth a combined $146M — up 31% from $112M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TVRD positions and 7 closed out — a net gain of 15 holders — while 32 added to existing stakes and 12 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.33M. The largest seller was Devon Park Associates, exiting entirely with an estimated $5.99M sold.
- 75 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2015, up from 60 in Q1 2015.
- Funds reported $146M of Tvardi Therapeutics stock for Q2 2015, up 31% quarter-over-quarter.
- 22 funds opened new Tvardi Therapeutics positions in Q2 2015 and 7 closed out, a net change of +15 holders.
- The largest Tvardi Therapeutics buyer in Q2 2015 was Millennium Management, an estimated $5.33M added.
- The largest Tvardi Therapeutics seller in Q2 2015 was Devon Park Associates, an estimated $5.99M sold.
Based on aggregated 13F filings for Q2 2015.